Literature DB >> 2799284

Gastric cancer detected by mass survey. Comparison between mass survey and outpatient detection.

G H Kampschöer1, A Fujii, Y Masuda.   

Abstract

Although the incidence of stomach cancer in Japan has decreased only slightly, the mortality has decreased markedly. The main reason for this success is the early diagnosis of cancer, to which mass survey has contributed. From 1964 to 1985, 290,914 screening examinations were done at the Mass Survey Center of the Cancer Institute Hospital, Tokyo. In 474 people (0.16%) cancer was detected, and of those, 52% were in an early stage of disease. For the mass survey group, the 5-year survival rate was 80%, and the 10-year survival rate 78.5%. The outpatient group rates were 56.2% and 55.1% for 5 and 10 years, respectively. This difference could be explained by the higher percentage of early gastric cancer and less extensive lymph node metastasis in patients with serosal involvement, in the outpatient group. The 10-year survival results show that early treatment results in an absolute better long-term survival. This refutes the hypothesis that 5-year survival rates of early gastric cancer patients are biased because of lead time of early diagnosis. Mass survey, even for a small district, provides an excellent opportunity to detect gastric cancer in people without symptoms. The high percentage of cases detected with cancer in an early stage reduces stomach cancer mortality.

Entities:  

Mesh:

Year:  1989        PMID: 2799284     DOI: 10.3109/00365528909089219

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  12 in total

1.  Comparing mass screening techniques for gastric cancer in Japan.

Authors:  Atsushi Tashiro; Masatoshi Sano; Koichi Kinameri; Kazutaka Fujita; Yutaka Takeuchi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

2.  Gastric precancerous lesions are associated with gene variants in Helicobacter pylori-susceptible ethnic Malays.

Authors:  Sathiya Maran; Yeong Yeh Lee; Shuhua Xu; Nur-Shafawati Rajab; Norhazrini Hasan; Syed Hassan Syed Abdul Aziz; Noorizan Abdul Majid; Bin Alwi Zilfalil
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

3.  Statistical analysis of serum pepsinogen I (PG I) and II (PG II) levels, PG I/PG II ratios and serum gastrin levels in a general population.

Authors:  A Kazuo; M Junichi
Journal:  Environ Health Prev Med       Date:  1996-10       Impact factor: 3.674

4.  Detection of early gastric cancer: misunderstanding the role of mass screening.

Authors:  Haruhisa Suzuki; Takuji Gotoda; Mitsuru Sasako; Daizo Saito
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

5.  The long term results of endoscopic surveillance of premalignant gastric lesions.

Authors:  J L Whiting; A Sigurdsson; D C Rowlands; M T Hallissey; J W L Fielding
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

6.  Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients.

Authors:  J J Bonenkamp; C J van de Velde; G H Kampschöer; J Hermans; P Hermanek; M Bemelmans; D J Gouma; M Sasako; K Maruyama
Journal:  World J Surg       Date:  1993 May-Jun       Impact factor: 3.352

Review 7.  The epidemiology of gastric cancer.

Authors:  David M Roder
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

Review 8.  Extended lymph node dissection (D2 resection) should now be performed routinely in the curative surgical treatment of gastric carcinoma.

Authors:  D Ravichandran; M Lamah; N J Carty; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1995-11       Impact factor: 1.891

9.  A clinicopathological study of asymptomatic gastric cancer.

Authors:  A Matsukuma; M Furusawa; H Tomoda; Y Seo
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

Review 10.  MicroRNAs as diagnostic biomarkers in gastric cancer.

Authors:  Ying Yin; Jun Li; Shujie Chen; Tianhua Zhou; Jianmin Si
Journal:  Int J Mol Sci       Date:  2012-10-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.